Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Catalyst Pharmaceuticals Return on Tangible Equity 2010-2025 | CPRX

Current and historical return on tangible equity values for Catalyst Pharmaceuticals (CPRX) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
  
Catalyst Pharmaceuticals Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2025-06-30 $0.21B $0.72B 34.39%
2025-03-31 $0.20B $0.65B 36.91%
2024-12-31 $0.16B $0.57B 34.97%
2024-09-30 $0.14B $0.50B 38.16%
2024-06-30 $0.07B $0.43B 22.95%
2024-03-31 $0.07B $0.38B 27.31%
2023-12-31 $0.07B $0.19B 39.72%
2023-09-30 $0.06B $0.18B 31.04%
2023-06-30 $0.12B $0.20B 54.27%
2023-03-31 $0.10B $0.15B 44.64%
2022-12-31 $0.08B $0.27B 34.37%
2022-09-30 $0.07B $0.24B 29.61%
2022-06-30 $0.05B $0.24B 24.91%
2022-03-31 $0.04B $0.22B 21.60%
2021-12-31 $0.04B $0.21B 20.16%
2021-09-30 $0.04B $0.20B 22.25%
2021-06-30 $0.07B $0.19B 42.59%
2021-03-31 $0.07B $0.18B 46.68%
2020-12-31 $0.07B $0.17B 55.02%
2020-09-30 $0.07B $0.16B 62.28%
2020-06-30 $0.04B $0.11B 44.56%
2020-03-31 $0.04B $0.10B 52.28%
2019-12-31 $0.03B $0.09B 45.71%
2019-09-30 $0.01B $0.08B 16.46%
2019-06-30 $-0.01B $0.06B -20.96%
2019-03-31 $-0.03B $0.05B -48.95%
2018-12-31 $-0.03B $0.05B -51.91%
2018-09-30 $-0.03B $0.06B -34.25%
2018-06-30 $-0.02B $0.07B -32.31%
2018-03-31 $-0.02B $0.08B -34.08%
2017-12-31 $-0.02B $0.08B -39.56%
2017-09-30 $-0.02B $0.03B -48.57%
2017-06-30 $-0.02B $0.03B -45.03%
2017-03-31 $-0.02B $0.04B -44.17%
2016-12-31 $-0.02B $0.04B -40.22%
2016-09-30 $-0.02B $0.04B -41.03%
2016-06-30 $-0.02B $0.05B -37.56%
2016-03-31 $-0.02B $0.05B -34.78%
2015-12-31 $-0.02B $0.06B -32.52%
2015-09-30 $-0.02B $0.06B -30.09%
2015-06-30 $-0.02B $0.06B -35.64%
2015-03-31 $-0.02B $0.07B -35.56%
2014-12-31 $-0.02B $0.04B -45.80%
2014-09-30 $-0.01B $0.04B -44.44%
2014-06-30 $-0.01B $0.04B -54.90%
2014-03-31 $-0.01B $0.02B -78.87%
2013-12-31 $-0.01B $0.02B -72.73%
2013-09-30 $-0.01B $0.02B -73.33%
2013-06-30 $-0.01B $0.01B -68.09%
2013-03-31 $-0.01B $0.01B -46.51%
2012-12-31 $0.00B $0.02B -48.48%
2012-09-30 $-0.01B $0.01B -109.09%
2012-06-30 $0.00B $0.01B -94.12%
2012-03-31 $-0.01B $0.00B -125.00%
2011-12-31 $-0.01B $0.00B -126.32%
2011-09-30 $-0.01B $0.00B -95.24%
2011-06-30 $-0.01B $0.01B -86.96%
2011-03-31 $-0.01B $0.01B -86.96%
2010-12-31 $0.00B $0.01B -66.67%
2010-09-30 $0.00B $0.01B -61.54%
2010-06-30 $0.00B $0.01B -64.00%
2010-03-31 $-0.01B $0.01B -76.92%
2009-12-31 $-0.01B $0.01B -103.70%
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $2.440B $0.492B
Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights to Firdapse (for treating LEMS) from BioMarin Pharmaceutical Inc. for its development and commercialization in the U.S. Firdapse is currently approved in the European Union and in the U.S. for treating of LEMS in adults. The company also plans to file a supplemental new drug application for Firdapse to treat pediatric patients with LEMS.?The company is also strengthening the commercial portfolio of Firdapse. It has already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population.?Apart from Firdapse, the company is working on a generic version of Lundbeck's Sabril, CPP-109, for the treatment of infantile spasms and complex partial seizures.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $70.099B 26.96
Zoetis (ZTS) United States $68.600B 24.89
Takeda Pharmaceutical (TAK) Japan $47.347B 9.66
Daiichi Sankyo, - (DSNKY) Japan $46.431B 23.80
BeOne Medicines - (ONC) Switzerland $33.857B 0.00
Sandoz Group AG (SDZNY) Switzerland $27.333B 0.00
Summit Therapeutics (SMMT) United States $20.042B 0.00
Merck (MKKGY) Germany $16.317B 10.61
Shionogi (SGIOY) Japan $14.615B 14.64
United Therapeutics (UTHR) United States $13.948B 12.07
Neurocrine Biosciences (NBIX) United States $13.572B 40.49
Orion OYJ (ORINY) Finland $11.336B 27.32
IPSEN (IPSEY) France $11.117B 0.00
Madrigal Pharmaceuticals (MDGL) United States $9.433B 0.00
Eisai (ESAIY) $9.158B 10.33
Corcept Therapeutics (CORT) United States $7.331B 61.57
Grifols, S.A (GRFS) Spain $6.766B 0.00
Ionis Pharmaceuticals (IONS) United States $6.722B 0.00
Stevanato Group S.p.A (STVN) Italy $6.557B 38.66
Ono Pharmaceutical (OPHLF) Japan $5.740B 19.71
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.436B 0.00
Soleno Therapeutics (SLNO) United States $3.699B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.946B 14.00
Crinetics Pharmaceuticals (CRNX) United States $2.913B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $2.837B 0.00
Hypermarcas (HYPMY) Brazil $2.755B 20.71
Centessa Pharmaceuticals (CNTA) United Kingdom $2.248B 0.00
Ocular Therapeutix (OCUL) United States $2.144B 0.00
Dyne Therapeutics (DYN) United States $1.903B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.801B 0.00
Guardian Pharmacy Services (GRDN) United States $1.648B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.607B 23.94
Ardelyx (ARDX) United States $1.494B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $1.442B 0.00
Harrow (HROW) United States $1.427B 0.00
ARS Pharmaceuticals (SPRY) United States $1.373B 0.00
Xeris Biopharma Holdings (XERS) United States $1.284B 0.00
Evotec AG (EVO) Germany $1.239B 0.00
Collegium Pharmaceutical (COLL) United States $1.215B 6.64
Enliven Therapeutics (ELVN) United States $1.204B 0.00
Cronos Group (CRON) Canada $0.977B 0.00
Akebia Therapeutics (AKBA) United States $0.819B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.817B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.747B 7.69
ProKidney (PROK) United States $0.700B 0.00
Theravance Biopharma (TBPH) United States $0.695B 57.50
KalVista Pharmaceuticals (KALV) United States $0.662B 0.00
Organogenesis (ORGO) United States $0.611B 0.00
Relay Therapeutics (RLAY) United States $0.610B 0.00
Siga Technologies (SIGA) United States $0.608B 7.51
Tourmaline Bio (TRML) United States $0.604B 0.00
Bioventus (BVS) United States $0.601B 14.54
Elite Pharmaceuticals (ELTP) United States $0.586B 0.00
USANA Health Sciences (USNA) United States $0.579B 11.87
Savara (SVRA) United States $0.572B 0.00
Xencor (XNCR) United States $0.563B 0.00
Oruka Therapeutics (ORKA) United States $0.555B 0.00
Nektar Therapeutics (NKTR) United States $0.547B 0.00
Zevra Therapeutics (ZVRA) United States $0.528B 0.00
Esperion Therapeutics (ESPR) United States $0.442B 0.00
Nanobiotix S.A (NBTX) France $0.402B 0.00
Aquestive Therapeutics (AQST) United States $0.389B 0.00
Aldeyra Therapeutics (ALDX) United States $0.353B 0.00
Larimar Therapeutics (LRMR) United States $0.320B 0.00
4D Molecular Therapeutics (FDMT) United States $0.305B 0.00
Altimmune (ALT) United States $0.304B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.298B 0.00
Nature's Sunshine Products (NATR) United States $0.291B 18.97
AleAnna (ANNA) United States $0.283B 0.00
Galectin Therapeutics (GALT) United States $0.266B 0.00
Lexeo Therapeutics (LXEO) United States $0.264B 0.00
Heron Therapeutics (HRTX) United States $0.216B 0.00
Lyell Immunopharma (LYEL) United States $0.211B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.206B 31.75
OmniAb (OABI) United States $0.198B 0.00
Aclaris Therapeutics (ACRS) United States $0.196B 0.00
Korro Bio (KRRO) United States $0.190B 0.00
MediWound (MDWD) Israel $0.182B 0.00
Journey Medical (DERM) United States $0.181B 0.00
China SXT Pharmaceuticals (SXTC) China $0.174B 0.00
Innate Pharma SA (IPHYF) France $0.173B 0.00
MEI Pharma (MEIP) United States $0.171B 0.00
Achieve Life Sciences (ACHV) Canada $0.159B 0.00
Wellgistics Health (WGRX) United States $0.145B 0.00
Inhibikase Therapeutics (IKT) United States $0.137B 0.00
Profound Medical (PROF) Canada $0.135B 0.00
Avalo Therapeutics (AVTX) United States $0.125B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.123B 0.00
Avita Medical (RCEL) United States $0.121B 0.00
Protara Therapeutics (TARA) United States $0.121B 0.00
Cassava Sciences (SAVA) United States $0.109B 0.00
Dominari Holdings (DOMH) United States $0.098B 0.00
Cardiol Therapeutics (CRDL) Canada $0.096B 0.00
Surrozen (SRZN) United States $0.095B 0.00
Champions Oncology (CSBR) United States $0.093B 21.03
BioNxt Solutions (BNXTF) Canada $0.087B 0.00
Pyxis Oncology (PYXS) United States $0.085B 0.00
Liminatus Pharma (LIMN) United States $0.085B 0.00
VAXART, INC (VXRT) United States $0.082B 0.00
Arch Biopartners (ACHFF) Canada $0.078B 0.00
Context Therapeutics (CNTX) United States $0.077B 0.00
PMV Pharmaceuticals (PMVP) United States $0.076B 0.00
Assertio Holdings (ASRT) United States $0.075B 0.00
Unicycive Therapeutics (UNCY) United States $0.075B 0.00
Nutriband (NTRB) United States $0.072B 0.00
Vivani Medical (VANI) United States $0.071B 0.00
Metagenomi (MGX) United States $0.070B 0.00
Prelude Therapeutics (PRLD) United States $0.069B 0.00
Gain Therapeutics (GANX) United States $0.069B 0.00
Karyopharm Therapeutics (KPTI) United States $0.065B 0.00
DURECT (DRRX) United States $0.060B 0.00
Inotiv (NOTV) United States $0.060B 0.00
Procaps Group, S.A (PROCF) Luxembourg $0.059B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.056B 0.00
PolyPid (PYPD) Israel $0.054B 0.00
Rafael Holdings (RFL) United States $0.054B 0.00
NRx Pharmaceuticals (NRXP) United States $0.052B 0.00
Jupiter Neurosciences (JUNS) United States $0.052B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.051B 30.91
Fractyl Health (GUTS) United States $0.051B 0.00
Plus Therapeutics (PSTV) United States $0.050B 0.00
Tempest Therapeutics (TPST) United States $0.049B 0.00
Telomir Pharmaceuticals (TELO) United States $0.048B 0.00
Klotho Neurosciences (KLTO) United States $0.045B 0.00
Century Therapeutics (IPSC) United States $0.044B 0.00
FibroGen (FGEN) United States $0.042B 0.00
Acrivon Therapeutics (ACRV) United States $0.042B 0.00
ElectroCore (ECOR) United States $0.041B 0.00
Mural Oncology (MURA) Ireland $0.036B 0.00
Vivos Therapeutics (VVOS) United States $0.035B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.035B 0.00
SCYNEXIS (SCYX) United States $0.034B 0.00
Iterum Therapeutics (ITRM) Ireland $0.031B 0.00
CASI Pharmaceuticals (CASI) China $0.028B 0.00
Enlivex Therapeutics (ENLV) Israel $0.026B 0.00
Cosmos Health (COSM) United States $0.025B 0.00
Natural Alternatives (NAII) United States $0.023B 0.00
Citius Pharmaceuticals (CTXR) United States $0.022B 0.00
Relmada Therapeutics (RLMD) United States $0.022B 0.00
Scienture Holdings (SCNX) United States $0.022B 0.00
Incannex Healthcare (IXHL) Australia $0.021B 0.00
Mangoceuticals (MGRX) United States $0.020B 0.00
Ainos (AIMD) United States $0.019B 0.00
Mannatech (MTEX) United States $0.017B 0.00
Lipocine (LPCN) United States $0.017B 0.00
BioLineRx (BLRX) Israel $0.015B 0.00
ProPhase Labs (PRPH) United States $0.014B 0.00
Aptorum Group (APM) United Kingdom $0.013B 0.00
TherapeuticsMD (TXMD) United States $0.013B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.013B 0.00
ESSA Pharma (EPIX) Canada $0.012B 0.00
BioVie (BIVI) United States $0.012B 0.00
Lyra Therapeutics (LYRA) United States $0.012B 0.00
Phio Pharmaceuticals (PHIO) United States $0.012B 0.00
Ernexa Therapeutics (ERNA) United States $0.011B 0.00
Talphera (TLPH) United States $0.011B 0.00
Heatwurx (PCSA) United States $0.011B 0.00
Traws Pharma (TRAW) United States $0.010B 0.02
Carisma Therapeutics (CARM) United States $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.010B 0.00
CERo Therapeutics Holdings (CERO) United States $0.009B 0.00
TransCode Therapeutics (RNAZ) United States $0.009B 0.00
Biomerica (BMRA) United States $0.008B 0.00
Addex Therapeutics (ADXN) Switzerland $0.008B 0.00
VYNE Therapeutics (VYNE) United States $0.008B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.008B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.008B 0.00
Vyome Holdings (HIND) United States $0.008B 0.00
Indaptus Therapeutics (INDP) United States $0.007B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.006B 0.00
Aditxt (ADTX) United States $0.005B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.005B 0.00
CDT Equity (CDT) United States $0.005B 0.00
InMed Pharmaceuticals (INM) Canada $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.004B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.004B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Alaunos Therapeutics (TCRT) United States $0.004B 0.00
Jaguar Animal Health (JAGX) United States $0.004B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.004B 0.00
PainReform (PRFX) Israel $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
Redhill Biopharma (RDHL) Israel $0.003B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.003B 0.00
SHINECO (SISI) China $0.003B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
SciSparc (SPRC) Israel $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.002B 0.00
TNF Pharmaceuticals (TNFA) United States $0.001B 0.00
Indivior (INDV) United States $0.000B 13.74
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Minerva Neurosciences (NERV) United States $0.000B 1.59
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00